Lyell Immunopharma holder transfers 38,500 shares

Rhea-AI Filing Summary

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, transferred 38,500 shares of common stock on July 27, 2026 to LifeSci Advisors, LLC as broker commission related to the first Development Milestone payment under a November 6, 2025 license agreement. This non-cash disposition, reported under transaction code J, reduced its beneficial holdings to 2,818,980 shares of Lyell common stock.

Insider Trade Summary

Other: 38,500 shares

Other 1 txn

Insider Innovative Cellular Therapeutics Holdings Ltd

Role 10% Owner

Type	Security	Shares	Price	Value
Other	Common Stock F1, F2	38,500	$0.00	$0.00

Holdings After Transaction: Common Stock — 2,818,980 shares (Direct)

Footnotes (2)

1. F1. Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
2. F2. Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred.

Key Figures

Shares transferred: 38,500 shares Shares beneficially owned before: 2,857,480 shares Shares beneficially owned after: 2,818,980 shares +1 more

4 metrics

Shares transferred 38,500 shares Common Stock transferred as broker commission on July 27, 2026

Shares beneficially owned before 2,857,480 shares Beneficial ownership immediately prior to the reported transaction

Shares beneficially owned after 2,818,980 shares Beneficial ownership following the 38,500-share transfer

Transaction price per share $0.0000 per share Transfer recorded with no cash consideration to the reporting person

Key Terms

Development Milestone, License Agreement, broker commission, beneficially owned

4 terms

Development Milestone financial

"in connection with the first Development Milestone payment"

License Agreement regulatory

"as defined in Section 6.2(a) of the License Agreement"

A license agreement is a contract where the owner of intellectual property, technology, a brand, or other rights gives another party permission to use those assets under specified conditions, usually for fees, royalties or other payments. For investors it matters because such deals create or limit predictable revenue streams, affect profit margins, transfer legal and commercial risk, and can determine how quickly a company can grow — like renting out a patented tool to earn steady income while keeping ownership.

broker commission financial

"transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission"

beneficially owned financial

"Reflects 2,857,480 shares of Common Stock beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Innovative Cellular Therapeutics report for Lyell Immunopharma (LYEL)?

Innovative Cellular Therapeutics Holdings Ltd reported transferring 38,500 shares of Lyell Immunopharma common stock on July 27, 2026. The shares went to LifeSci Advisors, LLC as broker commission tied to a license development milestone, reducing its beneficial ownership position.

How many Lyell Immunopharma (LYEL) shares were transferred and to whom?

The reporting person transferred 38,500 shares of Lyell Immunopharma common stock. These shares were delivered to LifeSci Advisors, LLC as a broker commission in connection with the first Development Milestone payment under a license agreement between the parties.

Why were the 38,500 Lyell Immunopharma (LYEL) shares transferred?

The 38,500 shares were transferred as broker commission in connection with the first Development Milestone payment under a License Agreement dated November 6, 2025 between Lyell Immunopharma and the reporting person, rather than as a standard market sale transaction.

How many LYEL shares does Innovative Cellular Therapeutics now beneficially own?

After the transaction, Innovative Cellular Therapeutics Holdings Ltd beneficially owns 2,818,980 shares of Lyell Immunopharma common stock. Footnotes state it previously held 2,857,480 shares and this amount was reduced by the 38,500 shares transferred as commission.

Did the reporting person receive cash for the LYEL shares transferred?

No cash was received by the reporting person for the 38,500 shares transferred. The footnote explains the transfer represented a broker commission to LifeSci Advisors, LLC and was a transfer of securities for no cash consideration to the reporting person.

What transaction code was used in this Lyell Immunopharma (LYEL) Form 4 filing?

The transaction used code J, described as “Other acquisition or disposition.” According to the disclosure, this code reflects the transfer of 38,500 shares as broker commission, a non-cash disposition rather than a typical open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/27/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Innovative Cellular Therapeutics Holdings Ltd

(Last) (First) (Middle)

190 ELGIN AVENUE

(Street)

GEORGE TOWN KY1-9008

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		J		38,500(1)	D	$0	2,818,980(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock transferred by the Reporting Person to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.

2. Reflects 2,857,480 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 38,500 shares transferred.

	Innovative Cellular Therapeutics Holdings Limited By: /s/ Lei Xiao Name: Lei Xiao Title: Chief Executive Officer	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)